NantKwest Inc. (NK) Upgraded by Zacks Investment Research to Hold
According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “
Several other equities research analysts have also commented on the company. Canaccord Genuity restated a buy rating and set a $18.00 price target on shares of NantKwest in a research note on Friday, August 19th. Piper Jaffray Cos. reaffirmed an overweight rating and issued a $23.00 target price (down previously from $32.00) on shares of NantKwest in a research report on Wednesday, August 17th. Finally, Raymond James Financial Inc. began coverage on NantKwest in a research report on Thursday, June 2nd. They issued a market perform rating for the company. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. NantKwest presently has an average rating of Buy and an average price target of $17.40.
Shares of NantKwest (NASDAQ:NK) traded down 2.69% on Wednesday, hitting $7.61. The stock had a trading volume of 35,044 shares. The company’s market cap is $626.39 million. The firm’s 50-day moving average is $8.00 and its 200-day moving average is $7.66. NantKwest has a one year low of $5.43 and a one year high of $19.43.
In other news, insider Barry J. Simon sold 32,000 shares of the stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $7.49, for a total transaction of $239,680.00. Following the sale, the insider now directly owns 3,334,906 shares in the company, valued at approximately $24,978,445.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 73.06% of the company’s stock.
A number of hedge funds have recently bought and sold shares of NK. TIAA CREF Investment Management LLC raised its position in shares of NantKwest by 12.8% in the first quarter. TIAA CREF Investment Management LLC now owns 21,223 shares of the company’s stock worth $174,000 after buying an additional 2,410 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of NantKwest by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 152,196 shares of the company’s stock worth $1,251,000 after buying an additional 3,309 shares during the last quarter. State Street Corp raised its position in shares of NantKwest by 23.2% in the first quarter. State Street Corp now owns 124,630 shares of the company’s stock worth $1,025,000 after buying an additional 23,497 shares during the last quarter. Geode Capital Management LLC raised its position in shares of NantKwest by 3.5% in the first quarter. Geode Capital Management LLC now owns 88,365 shares of the company’s stock worth $726,000 after buying an additional 2,998 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of NantKwest during the first quarter worth about $137,000. Hedge funds and other institutional investors own 24.13% of the company’s stock.
NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.
Receive News & Stock Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related stocks with our FREE daily email newsletter.